Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) CFO Oluyemi Okupe sold 3,518 shares of the company’s stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $18.53, for a total value of $65,188.54. Following the transaction, the chief financial officer directly owned 266,188 shares in the company, valued at approximately $4,932,463.64. This trade represents a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oluyemi Okupe also recently made the following trade(s):
- On Thursday, October 1st, Oluyemi Okupe sold 2,000 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.70, for a total transaction of $59,400.00.
- On Tuesday, September 22nd, Oluyemi Okupe sold 29,277 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.95, for a total value of $876,846.15.
- On Thursday, September 17th, Oluyemi Okupe sold 12,313 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.82, for a total value of $354,860.66.
Hims & Hers Health Stock Down 2.5%
HIMS traded down $0.43 during mid-day trading on Wednesday, reaching $17.12. 9,531,665 shares of the stock were exchanged, compared to its average volume of 22,172,965. The company has a 50 day moving average price of $27.21 and a two-hundred day moving average price of $26.59. The stock has a market capitalization of $4.01 billion, a PE ratio of -20.63 and a beta of 2.53. The company has a debt-to-equity ratio of 3.85, a quick ratio of 0.84 and a current ratio of 0.92. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $40.99.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. MassMutual Private Wealth & Trust FSB grew its holdings in Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after purchasing an additional 319 shares during the period. Sigma Planning Corp increased its position in Hims & Hers Health by 1.5% in the first quarter. Sigma Planning Corp now owns 26,007 shares of the company’s stock worth $540,000 after buying an additional 388 shares in the last quarter. Western Wealth Management LLC raised its stake in shares of Hims & Hers Health by 6.8% in the third quarter. Western Wealth Management LLC now owns 9,072 shares of the company’s stock worth $270,000 after buying an additional 580 shares during the period. Insigneo Advisory Services LLC raised its stake in shares of Hims & Hers Health by 9.6% in the third quarter. Insigneo Advisory Services LLC now owns 6,796 shares of the company’s stock worth $202,000 after buying an additional 594 shares during the period. Finally, Versant Capital Management Inc raised its stake in shares of Hims & Hers Health by 801.2% in the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after buying an additional 665 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.
Latest Hims & Hers Health News
These are some of the HIMS news items that stood out recently:
- Positive Sentiment: Hims & Hers launched Peptides+, adding five provider-guided treatments—sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine—to its telehealth offerings. The company also plans twice-yearly lab testing and ongoing medical-team support through Care+, expanding its services into cellular health and wellness. Hims & Hers launches new peptide treatments — while admitting there’s more to learn about efficacy
- Negative Sentiment: The new peptide treatments are not FDA-approved, and the company acknowledged that more remains to be learned about their efficacy. That uncertainty could temper enthusiasm for the launch. Hims & Hers launches new peptide treatments while admitting there’s more to learn about efficacy
- Negative Sentiment: Recent coverage points to pressure from slipping profit and a reported loss of 100,000 subscribers, which may weigh on sentiment even as Hims & Hers adds obesity-drug access and other services. Hims & Hers Stock Fell 32% As Profit Slipped Hims & Hers Lost 100K Subscribers Before Adding Eli Lilly’s $299 Zepbound
Analyst Ratings Changes
A number of analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings reiterated a “sell (d)” rating on shares of Hims & Hers Health in a research note on Wednesday, November 4th. Barclays reduced their target price on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating for the company in a research report on Friday, August 21st. TD Cowen raised their price target on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a research note on Tuesday, August 11th. Finally, Jefferies Financial Group lowered their price target on shares of Hims & Hers Health from $31.00 to $24.00 and set a “hold” rating on the stock in a report on Tuesday, November 10th. Three investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $31.53.
Get Our Latest Stock Report on HIMS
Hims & Hers Health Company Profile
Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.
Featured Articles
- Five stocks we like better than Hims & Hers Health
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
